Profiling Genome-Wide DNA Methylation in Children with Autism Spectrum Disorder and in Children with Fragile X Syndrome
Open Access
Abstract
Autism spectrum disorder (ASD) is an early onset, developmental disorder whose genetic cause is heterogeneous and complex. In total, 70% of ASD cases are due to an unknown etiology. Among the monogenic causes of ASD, fragile X syndrome (FXS) accounts for 2–4% of ASD cases, and 60% of individuals with FXS present with ASD. Epigenetic changes, specifically DNA methylation, which modulates gene expression levels, play a significant role in the pathogenesis of both disorders. Thus, in this study, using the Human Methylation EPIC Bead Chip, we examined the global DNA methylation profiles of biological samples derived from 57 age-matched male participants (2–6 years old), including 23 subjects with ASD, 23 subjects with FXS with ASD (FXSA) and 11 typical developing (TD) children. After controlling for technical variation and white blood cell composition, using the conservatory threshold of the false discovery rate (FDR ≤ 0.05), in the three comparison groups, TD vs. AD, TD vs. FXSA and ASD vs. FXSA, we identified 156, 79 and 3100 differentially methylated sites (DMS), and 14, 13 and 263 differential methylation regions (DMRs). Interestingly, several genes differentially methylated among the three groups were among those listed in the SFARI Gene database, including the PAK2, GTF2I and FOXP1 genes important for brain development. Further, enrichment analyses identified pathways involved in several functions, including synaptic plasticity. Our preliminary study identified a significant role of altered DNA methylation in the pathology of ASD and FXS, suggesting that the characterization of a DNA methylation signature may help to unravel the pathogenicity of FXS and ASD and may help the development of an improved diagnostic classification of children with ASD and FXSA. In addition, it may pave the way for developing therapeutic interventions that could reverse the altered methylome profile in children with neurodevelopmental disorders.Keywords
Funding Information
- National Institute of Health (GM113929-01, P50HD103526, UL1TR001860, R40MC27701)
- Health Resources & Services Administration (GM113929-01, P50HD103526, UL1TR001860, R40MC27701)
This publication has 72 references indexed in Scilit:
- The Fragile X Protein binds mRNAs involved in cancer progression and modulates metastasis formationEMBO Molecular Medicine, 2013
- Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486Proceedings of the National Academy of Sciences, 2013
- De Novo Gene Disruptions in Children on the Autistic SpectrumNeuron, 2012
- Dysregulation of fragile × mental retardation protein and metabotropic glutamate receptor 5 in superior frontal cortex of individuals with autism: a postmortem brain studyMolecular Autism, 2011
- Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysisBMC Bioinformatics, 2010
- The Conceptual Development of DSM-VAmerican Journal of Psychiatry, 2009
- Standardizing ADOS Scores for a Measure of Severity in Autism Spectrum DisordersJournal of Autism and Developmental Disorders, 2008
- Expression of 24,426 human alternative splicing events and predicted cis regulation in 48 tissues and cell linesNature Genetics, 2008
- Reduced Oxidative Stress Promotes NF-κB-Mediated Neuroprotective Gene Expression after Transient Focal Cerebral Ischemia: Lymphocytotrophic Cytokines and Antiapoptotic FactorsJournal of Cerebral Blood Flow & Metabolism, 2007
- DNA methylation patterns and epigenetic memoryGenes & Development, 2002